Drug Trial Radar · NCT00211224
Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)
Last checked: Nov 20, 2026Latest source record: Dec 15, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
800
Actual
Start
Apr 2000
Primary completion
Not stated
Study completion Nov 2004
Sponsor
- Lead sponsor
- King's College LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Assistance Publique - Hôpitaux de Paris; University of Ulm; Aventis Pharmaceuticals
- First posted
- Sep 21, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
NNIPPS is a clinical trial of riluzole (a drug previously shown to slow down the rate of progression og amyotrophic lateral sclerosis-ALS; Lou Gehrig's disease) involving nearly 800 people diagnosed with the 'parkinson plus' syndromes of multiple system atrophy (MSA) and progressive supranuclear plasy (PSP). In addition to showing whether riluzole is helpful in MSA and PSP, NNIPPS will improve criteria for making an accurate and early diagnosis, for assessing the rate of progression, and will advance understanding of the biology of these disabling and progressive neurodegenerative diseases.
Conditions
- Multiple System Atrophy
- Progressive Supranuclear Palsy
Interventions
RiluzoleDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- survival
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Psychiatry, King's College London
London, London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.